527 related articles for article (PubMed ID: 15144526)
1. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
2. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
4. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
5. Evaluation and validation of virus removal by ultrafiltration during the production of diaspirin crosslinked haemoglobin (DCLHb).
Azari M; Boose JA; Burhop KE; Camacho T; Catarello J; Darling A; Ebeling AA; Estep TN; Pearson L; Guzder S; Herren J; Ogle K; Paine J; Rohn K; Sarajari R; Sun CS; Zhang L
Biologicals; 2000 Jun; 28(2):81-94. PubMed ID: 10885615
[TBL] [Abstract][Full Text] [Related]
6. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
7. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
8. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
9. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of the virus-elimination efficacy of nanofiltration (Viresolve NFP) for the parvovirus B19 and hepatitis A virus].
Oh DJ; Lee YL; Kang JW; Kwon SY; Cho NS; Kim IS
Korean J Lab Med; 2010 Feb; 30(1):45-50. PubMed ID: 20197722
[TBL] [Abstract][Full Text] [Related]
11. Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.
Omar A; Kempf C
Transfusion; 2002 Aug; 42(8):1005-10. PubMed ID: 12385411
[TBL] [Abstract][Full Text] [Related]
12. Porcine parvovirus flocculation and removal in the presence of osmolytes.
Gencoglu MF; Pearson E; Heldt CL
J Biotechnol; 2014 Sep; 186():83-90. PubMed ID: 25003646
[TBL] [Abstract][Full Text] [Related]
13. An assay for parvovirus B19 neutralizing antibodies based on human hepatocarcinoma cell lines.
Caillet-Fauquet P; Di Giambattista M; Draps ML; Hougardy V; de Launoit Y; Laub R
Transfusion; 2004 Sep; 44(9):1340-3. PubMed ID: 15318858
[TBL] [Abstract][Full Text] [Related]
14. Effects of lyophilization on the infectivity of enveloped and non-enveloped viruses in bone tissue.
Uhlenhaut C; Dörner T; Pauli G; Pruss A
Biomaterials; 2005 Nov; 26(33):6558-64. PubMed ID: 15946737
[TBL] [Abstract][Full Text] [Related]
15. Virus removal from factor IX by filtration: validation of the integrity test and effect of manufacturing process conditions.
Roberts PL; Feldman P; Crombie D; Walker C; Lowery K
Biologicals; 2010 Mar; 38(2):303-10. PubMed ID: 20089418
[TBL] [Abstract][Full Text] [Related]
16. Dry-heat treatment process for enhancing viral safety of an antihemophilic factor VIII concentrate prepared from human plasma.
Kim IS; Choi YW; Kang Y; Sung HM; Shin JS
J Microbiol Biotechnol; 2008 May; 18(5):997-1003. PubMed ID: 18633304
[TBL] [Abstract][Full Text] [Related]
17. Virus inactivation and protein recovery in a novel ultraviolet-C reactor.
Wang J; Mauser A; Chao SF; Remington K; Treckmann R; Kaiser K; Pifat D; Hotta J
Vox Sang; 2004 May; 86(4):230-8. PubMed ID: 15144527
[TBL] [Abstract][Full Text] [Related]
18. A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance.
Parkkinen J; Rahola A; von Bonsdorff L; Tölö H; Törmä E
Vox Sang; 2006 Feb; 90(2):97-104. PubMed ID: 16430667
[TBL] [Abstract][Full Text] [Related]
19. Robustness of nanofiltration for increasing the viral safety margin of biological products.
Caballero S; Diez JM; Belda FJ; Otegui M; Herring S; Roth NJ; Lee D; Gajardo R; Jorquera JI
Biologicals; 2014 Mar; 42(2):79-85. PubMed ID: 24485384
[TBL] [Abstract][Full Text] [Related]
20. Removal of parvovirus B19 from hemoglobin solution by nanofiltration.
Abe H; Sugawara H; Hirayama J; Ihara H; Kato T; Ikeda H; Ikebuchi K
Artif Cells Blood Substit Immobil Biotechnol; 2000 Sep; 28(5):375-83. PubMed ID: 11009110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]